Browse by Series:

FDA Approval Sought in Multiple Myeloma, 2017 AACR Annual Meeting Highlights, and More

Patrick Borgen, MD
Published: Thursday, Apr 13, 2017



Patrick Borgen, MD, discusses an FDA approval sought for an agent in multiple myeloma, impressive phase III findings in non–small cell lung cancer, a change in USPSTF recommendations for PSA screening, and highlights from the 2017 AACR Annual Meeting.
SELECTED
LANGUAGE
Slider Left
Slider Right


Patrick Borgen, MD, discusses an FDA approval sought for an agent in multiple myeloma, impressive phase III findings in non–small cell lung cancer, a change in USPSTF recommendations for PSA screening, and highlights from the 2017 AACR Annual Meeting.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Rapid Reviews in Oncology®: Practice-Changing Data in Acute Myeloid Leukemia: A Rapid Update From Atlanta OnlineDec 21, 20182.0
Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesDec 30, 20182.0
Publication Bottom Border
Border Publication
x